Sorrento Therapeutics, Inc.
CD38 antibody drug conjugate

Last updated:

Abstract:

There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.

Status:
Grant
Type:

Utility

Filling date:

20 Jun 2018

Issue date:

7 Dec 2021